如何治疗激素难治性急性移植物抗宿主病
作者强调避免伤害的 imperative,并呼吁开展广泛可及的前瞻性试验。
要点
- SR-aGVHD是异基因造血细胞移植后的严峻挑战,回顾性研究远多于前瞻性研究。
- 无对照前瞻性试验显示任何药物优于其他药物。
- 当前知识有限,治疗核心是避免伤害,亟需广泛可及的前瞻性试验。
核心结论
- 目前尚无对照前瞻性试验证明任何药物优于其他药物,SR-aGVHD治疗知识有限。
- 作者强调在SR-aGVHD照护中避免伤害是首要原则,亟需广泛可及的前瞻性试验推进领域发展。
主要发现
- 回顾性研究远多于前瞻性研究,且无对照前瞻性试验显示任何药物优于其他药物。
- 近十年临床前工作为急性GVHD发病机制提供新见解,向SR-aGVHD更有效治疗的转化已开始。
临床怎么用
- 临床中应优先避免伤害,不依赖未经验证的免疫抑制策略。
- 应推动患者参与广泛可及的前瞻性试验以改善SR-aGVHD治疗证据。
局限性
- 当前知识有限,缺乏对照前瞻性试验证据。
- 回顾性研究占主导,无法确定任一药物优于其他。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Steroid-resistant or steroid-refractory acute graft-versus-host disease (SR-aGVHD) poses one of the most vexing challenges faced by providers who care for patients after allogeneic hematopoietic cell transplantation. For the past 4 decades, research in the field has been driven by the premise that persistent graft-versus-host disease (GVHD) results from inadequate immunosuppression. Accordingly, most efforts to solve this problem have relied on retrospective or prospective studies testing agents that have direct or indirect immunosuppressive effects. Retrospective studies far outnumber prospective studies, and no controlled prospective trial has shown superior results for any agent over others. Truth be told, I do not know how to treat SR-aGVHD. Preclinical work during the past decade has provided fresh insights into the pathogenesis of acute GVHD, and translation of these insights toward development of more effective treatments for patients with SR-aGVHD has at last begun. Given the limited state of current knowledge, this "How I Treat" review highlights the overriding imperative to avoid harm in caring for patients with SR-aGVHD. Prospective trials that are widely available are urgently needed to advance the field.
引用
- Martin PJ. How I treat steroid-refractory acute graft-versus-host disease. Blood. 2020. PMID: 32202630. doi:10.1182/blood.2019000960
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。